000141916 001__ 141916
000141916 005__ 20240229105135.0
000141916 0247_ $$2doi$$a10.1111/ejh.13100
000141916 0247_ $$2pmid$$apmid:29797671
000141916 0247_ $$2ISSN$$a0036-553X
000141916 0247_ $$2ISSN$$a0902-4441
000141916 0247_ $$2ISSN$$a1600-0609
000141916 0247_ $$2altmetric$$aaltmetric:43234918
000141916 037__ $$aDKFZ-2018-02173
000141916 041__ $$aeng
000141916 082__ $$a610
000141916 1001_ $$00000-0002-3620-1491$$aKriegsmann, Katharina$$b0
000141916 245__ $$aCD7 is expressed on a subset of normal CD34-positive myeloid precursors.
000141916 260__ $$aOxford$$bWiley-Blackwell$$c2018
000141916 3367_ $$2DRIVER$$aarticle
000141916 3367_ $$2DataCite$$aOutput Types/Journal article
000141916 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1544518621_4510
000141916 3367_ $$2BibTeX$$aARTICLE
000141916 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141916 3367_ $$00$$2EndNote$$aJournal Article
000141916 520__ $$aTo improve monitoring of myeloid neoplasms by flow cytometry-based minimal residual disease (MRD) analysis, we analyzed the significance of leukemia-associated immunophenotype (LAIP) markers in 44 patients.In a pilot study cohort, peripheral blood or bone marrow samples from 13 patients with myeloid neoplasms and one case of B lymphoblastic leukemia in complete hematologic remission after allogeneic bone marrow or stem cell transplantation were subjected to selection for leukemia-specific phenotypes by fluorescence-activated cell sorting using individual marker combinations, followed by PCR-based chimerism analysis.The feasibility of this method could be demonstrated, with selection being successful in 12 cases, including two cases where mixed chimerism was found exclusively in sorted cells. Interestingly, four specimens displayed full donor chimerism in cells expressing the presumably aberrant combination CD34+ /CD7+ . Further analyses, including assessment of an independent cohort of 25 patients not affected by neoplastic bone marrow infiltration, revealed that normal myeloid precursors usually include a population coexpressing CD34, CD13, CD33, and CD7.We conclude that the combination CD34+ /CD7+ might not be suitable as an LAIP for MRD diagnostics and that a subset of normal myeloid precursors in the bone marrow expresses CD7.
000141916 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000141916 588__ $$aDataset connected to CrossRef, PubMed,
000141916 7001_ $$0P:(DE-He78)3d0bd280b309d8ef615f728f271a8595$$aLöffler, Harald$$b1$$udkfz
000141916 7001_ $$aEckstein, Volker$$b2
000141916 7001_ $$aSchulz, Renate$$b3
000141916 7001_ $$aKräker, Sandra$$b4
000141916 7001_ $$aBraun, Ute$$b5
000141916 7001_ $$aLuft, Thomas$$b6
000141916 7001_ $$aHegenbart, Ute$$b7
000141916 7001_ $$aSchönland, Stefan$$b8
000141916 7001_ $$aDreger, Peter$$b9
000141916 7001_ $$0P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0$$aKrämer, Alwin$$b10$$udkfz
000141916 7001_ $$aHo, Anthony D$$b11
000141916 7001_ $$aMüller-Tidow, Carsten$$b12
000141916 7001_ $$aHundemer, Michael$$b13
000141916 773__ $$0PERI:(DE-600)2027114-1$$a10.1111/ejh.13100$$gVol. 101, no. 3, p. 318 - 325$$n3$$p318 - 325$$tEuropean journal of haematology$$v101$$x0902-4441$$y2018
000141916 909CO $$ooai:inrepo02.dkfz.de:141916$$pVDB
000141916 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d0bd280b309d8ef615f728f271a8595$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000141916 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000141916 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000141916 9141_ $$y2018
000141916 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J HAEMATOL : 2017
000141916 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141916 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141916 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141916 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000141916 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000141916 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141916 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141916 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141916 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141916 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000141916 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000141916 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141916 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000141916 9201_ $$0I:(DE-He78)G330-20160331$$kG330$$lKKE Molekulare Hämatologie/Onkologie$$x0
000141916 980__ $$ajournal
000141916 980__ $$aVDB
000141916 980__ $$aI:(DE-He78)G330-20160331
000141916 980__ $$aUNRESTRICTED